sPLA2 (mouse Type V) Polyclonal Antibody

Secretory phospholipase A2 (sPLA2) (Type V) is a calcium-dependent phospholipase A2 superfamily member that is encoded by PLA2G5 in humans.{56210} It is composed of a highly conserved calcium-binding loop, a heparin-binding domain, and a C-terminal domain that contains a catalytic histidine-aspartic acid dyad and cationic residues that are essential for cell membrane association. Pla2g5 is constitutively expressed in the heart, lung, and spleen and is induced by proinflammatory stimuli in a variety of immune cells and tissues.{12947} Upon activation, sPLA2 (Type V) is released into the extracellular space where it acts in a paracrine or autocrine manner to catalyze the hydrolysis of fatty acids at the sn-2 position of glycerophospholipids, liberating the free fatty acid and lysophospholipid, which serve as substrates for the synthesis of bioactive lipid metabolites.{56210} Pla2g5-/- mice have decreased airway and bronchoalveolar lavage fluid (BALF) neutrophil infiltration in a model of acute lung injury induced by LPS.{56211} Neonatal mice overexpressing Pla2g5 have increased BALF prostaglandin E2 (PGE2; Item No. 14010) levels, as well as reduced lung surfactant levels, leading to respiratory failure and death by postnatal day one.{56212} SNPs in PLA2G5 are associated with increased plasma LDL and total cholesterol levels in individuals with type 2 diabetes.{56213} Cayman's sPLA2 (mouse Type V) Polyclonal Antibody can be used for Western blot applications. The antibody recognizes sPLA2 (Type V) at 16 kDa from human, mouse, and rat samples.